Have your own idea? Try our Stock Screener
U.S. Biotech Industry Analysis
UpdatedMay 23, 2025
DataAggregated Company Financials
Companies567
- 7D2.7%
- 3M-11.3%
- 1Y-13.0%
- YTD-6.0%
The Biotech industry is up 2.7% in the last week, with Gilead Sciences up 6.4%. Meanwhile, Exelixis actually underperformed within the industry, shrinking 7.3% in the last week. In the past year, the industry is down 13%. As for the next few years, earnings are expected to grow by 24% per annum.
Industry Valuation and Performance
Has the U.S. Biotech Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Fri, 23 May 2025 | US$907.8b | US$155.9b | -US$24,354,722,512.98 | 15.6x | -37.3x | 5.8x |
| Sun, 20 Apr 2025 | US$756.8b | US$119.2b | -US$36,619,881,205.07 | 19.4x | -20.7x | 6.3x |
| Tue, 18 Mar 2025 | US$839.1b | US$118.4b | -US$37,618,768,555.54 | 19.9x | -22.3x | 7.1x |
| Thu, 13 Feb 2025 | US$815.2b | US$118.2b | -US$35,533,913,315.57 | 17x | -22.9x | 6.9x |
| Sat, 11 Jan 2025 | US$967.2b | US$149.4b | -US$26,283,970,082.71 | 16.6x | -36.8x | 6.5x |
| Mon, 09 Dec 2024 | US$1.0t | US$150.0b | -US$26,481,489,967.01 | 17.9x | -39.1x | 6.9x |
| Wed, 06 Nov 2024 | US$1.1t | US$148.1b | -US$30,555,050,448.51 | 16.6x | -34.9x | 7.2x |
| Fri, 04 Oct 2024 | US$891.6b | US$113.2b | -US$35,958,059,033.08 | 22x | -24.8x | 7.9x |
| Sun, 01 Sep 2024 | US$909.4b | US$113.1b | -US$35,712,101,098.38 | 24x | -25.5x | 8x |
| Tue, 30 Jul 2024 | US$1.2t | US$164.9b | -US$28,963,503,229.83 | 26.8x | -43x | 7.5x |
| Thu, 27 Jun 2024 | US$1.2t | US$164.4b | -US$27,986,453,486.34 | 27.7x | -41.4x | 7x |
| Sat, 25 May 2024 | US$1.1t | US$164.6b | -US$26,747,196,206.43 | 23.8x | -42.1x | 6.8x |
| Mon, 22 Apr 2024 | US$1.1t | US$164.2b | -US$23,311,155,066.52 | 20.4x | -45.9x | 6.5x |
| Wed, 20 Mar 2024 | US$1.2t | US$167.4b | -US$21,814,367,317.91 | 13.8x | -53.5x | 7x |
| Fri, 16 Feb 2024 | US$1.2t | US$169.1b | -US$20,723,712,339.70 | 18.7x | -55.6x | 6.8x |
| Sun, 14 Jan 2024 | US$1.4t | US$204.8b | -US$22,497,556,941.00 | 18.8x | -63.9x | 7x |
| Tue, 12 Dec 2023 | US$1.3t | US$204.6b | -US$22,091,146,901.00 | 18.7x | -58.6x | 6.3x |
| Thu, 09 Nov 2023 | US$1.2t | US$204.1b | -US$20,943,935,957.00 | 16.6x | -59.3x | 6.1x |
| Sat, 07 Oct 2023 | US$1.3t | US$207.4b | -US$13,060,168,797.00 | 17.2x | -96.3x | 6.1x |
| Mon, 04 Sep 2023 | US$1.3t | US$207.6b | -US$12,421,503,459.00 | 18.4x | -104.2x | 6.2x |
| Wed, 02 Aug 2023 | US$1.1t | US$186.2b | -US$14,964,083,330.00 | 14.7x | -76.4x | 6.1x |
| Fri, 30 Jun 2023 | US$1.1t | US$186.2b | -US$16,044,205,476.00 | 13.6x | -69.4x | 6x |
| Sun, 28 May 2023 | US$1.1t | US$185.9b | -US$16,045,698,796.00 | 11.2x | -69.9x | 6x |
| Tue, 25 Apr 2023 | US$1.2t | US$198.6b | -US$3,172,070,914.00 | 13.7x | -374.7x | 6x |
| Thu, 23 Mar 2023 | US$1.1t | US$199.5b | -US$3,522,273,239.00 | 12.4x | -313.9x | 5.5x |
| Sat, 18 Feb 2023 | US$1.2t | US$202.6b | -US$64,851,937.00 | 16.5x | -17785.7x | 5.7x |
| Mon, 16 Jan 2023 | US$1.2t | US$203.7b | US$1.8b | 14.5x | 670.9x | 5.8x |
| Wed, 14 Dec 2022 | US$1.2t | US$202.9b | US$1.5b | 14.8x | 792.8x | 5.8x |
| Fri, 11 Nov 2022 | US$1.1t | US$201.7b | US$975.9m | 14.1x | 1133.1x | 5.5x |
| Sun, 09 Oct 2022 | US$1.0t | US$206.1b | US$5.4b | 14.9x | 190.3x | 5x |
| Tue, 06 Sep 2022 | US$1.0t | US$206.1b | US$6.1b | 14.6x | 171.4x | 5x |
| Thu, 04 Aug 2022 | US$1.1t | US$212.1b | US$10.6b | 16x | 102.1x | 5.1x |
| Sat, 02 Jul 2022 | US$1.1t | US$212.1b | US$11.0b | 15.8x | 95.5x | 5x |
| Mon, 30 May 2022 | US$1.0t | US$212.7b | US$11.2b | 15.5x | 91.6x | 4.8x |
Price to Earnings Ratio
91.6x
Current Industry PE
- Investors are relatively neutral on the American Biotechs industry at the moment, indicating that they anticipate long term growth rates to remain steady.
- The industry is trading close to its 3-year average PS ratio of 6.3x.
Past Earnings Growth
- Total earnings for the Biotechs industry have declined over the last three years, with the industry now making a loss overall.
- Revenues have also declined 9.8% per year, which is driving profits down.
Industry Trends
Which industries have driven the changes within the U.S. Healthcare industry?
| US Market | -1.37% | |
| Healthcare | -0.051% | |
| Biotech | 2.72% | |
| Biotech | 2.72% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| GILD Gilead Sciences | US$106.74 | 6.4% +US$8.0b | 61.3% | PE22.3x | |
| SMMT Summit Therapeutics | US$25.77 | 11.6% +US$2.0b | 496.5% | PB55.6x | |
| BNTX BioNTech | US$99.07 | 7.3% +US$1.6b | 0.07% | PS7.7x | |
| ABBV AbbVie | US$182.54 | 0.5% +US$1.5b | 15.3% | PE77.6x | |
| ONC BeiGene | US$238.76 | 5.8% +US$1.4b | 52.9% | PS6.2x |
